We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+23%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
-$697M
Cap. Flow
-$415M
Cap. Flow %
-21.46%
Top 10 Hldgs %
57.89%
Holding
87
New
13
Increased
14
Reduced
17
Closed
30

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$87.5M
2
SPTX
Seaport Therapeutics
SPTX
+$62.7M
3
GILD icon
Gilead Sciences
GILD
+$45.2M
4
ANAB icon
AnaptysBio
ANAB
+$14.9M
5
ABT icon
Abbott
ABT
+$11.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$89.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$63.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$51M
4
UTHR icon
United Therapeutics
UTHR
+$47.1M
5
BIIB icon
Biogen
BIIB
+$42.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.78%
2 Miscellaneous 3.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
51
Wave Life Sciences
WVE
$948M
$1.1M 0.06%
189,253
– –
AKTS
52
Aktis Oncology
AKTS
$1.34B
$1.05M 0.05%
+32,436
New +$666K
TYRA icon
53
Tyra Biosciences
TYRA
$1.31B
$1.03M 0.05%
32,267
-171,748
-84% -$5.68M
BOLT icon
54
Bolt Biotherapeutics
BOLT
$7.09M
$530K 0.03%
137,721
– –
NXTC icon
55
NextCure
NXTC
$36.9M
$356K 0.02%
222,654
– –
IMA
56
ImageneBio Inc
IMA
$56.9M
$188K 0.01%
31,884
– –
HTFL
57
Heartflow Inc
HTFL
$4.06B
$149K 0.01%
+5,079
New +$153K
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$4.77B
– –
-78,551
Closed -$1.75M
AXGN icon
59
Axogen
AXGN
$2.54B
– –
-210,665
Closed -$6.98M
AXSM icon
60
PUT
Axsome Therapeutics
AXSM
$11B
– –
-200,000
Closed -$33.8M
AZN icon
61
AstraZeneca
AZN
$243B
– –
-456,031
Closed -$89.9M
BBIO icon
62
BridgeBio Pharma
BBIO
$14.9B
– –
-409,183
Closed -$30.4M
BIIB icon
63
Biogen
BIIB
$31.1B
– –
-229,521
Closed -$42.1M
CELC icon
64
Celcuity
CELC
$4.41B
– –
-366,175
Closed -$41.8M
CELC icon
65
PUT
Celcuity
CELC
$4.41B
– –
-300,000
Closed -$34.2M
CMPX icon
66
CALL
Compass Therapeutics
CMPX
$393M
– –
-500,000
Closed -$2.65M
CMPX icon
67
Compass Therapeutics
CMPX
$393M
– –
-2,056,161
Closed -$10.9M
CYTK icon
68
Cytokinetics
CYTK
$10.3B
– –
-91,791
Closed -$6.05M
DXCM icon
69
DexCom
DXCM
$31.7B
– –
-393,576
Closed -$24.7M
ESTA icon
70
Establishment Labs
ESTA
$2.22B
– –
-33,930
Closed -$1.93M
HRMY icon
71
Harmony Biosciences
HRMY
$2.42B
– –
-152,695
Closed -$4.28M
IBB icon
72
PUT
iShares Biotechnology ETF
IBB
$10.4B
– –
-475,000
Closed -$80.2M
IWM icon
73
PUT
iShares Russell 2000 ETF
IWM
$79B
– –
-600,000
Closed -$149M
LQDA icon
74
PUT
Liquidia Corp
LQDA
$6.19B
– –
-500,000
Closed -$18.9M
ORIC icon
75
Oric Pharmaceuticals
ORIC
$1.3B
– –
-679,578
Closed -$8.61M
1 2
3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Sofinnova Investments held 87 positions worth $1.93B, down 26% from $2.63B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments withdrew a net $415M in Q2 2026, closing 30 positions and reducing 17 holdings. Its most notable exit was AstraZeneca, an estimated $89.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, Sofinnova Investments opened a new position in Seaport Therapeutics worth $77.4M.

  • Sofinnova Investments's largest Q2 2026 buy was Seaport Therapeutics: 3,564,871 shares worth $77.4M.
  • Sofinnova Investments added most to Genmab in Q2 2026, an estimated $87.5M increase.
  • Sofinnova Investments's biggest Q2 2026 reduction was Bristol-Myers Squibb, cutting an estimated $63.8M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2026, selling an estimated $89.9M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.93B portfolio in Q2 2026.
  • Sofinnova Investments opened 13 new positions and closed 30 in Q2 2026.
  • Sofinnova Investments's portfolio value fell 26% quarter-over-quarter to $1.93B.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.